LXRXLexicon Pharmaceuticals, Inc.

$710M

FY 2012 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M-41.1% YoY

Gross Profit

-$81M-7482.6% margin

Operating Income

-$108M-9955.5% margin

Net Income

-$110M-10120.4% margin

EPS (Diluted)

$-1.58

Cash Flow

Operating Cash Flow

-$94M

Free Cash Flow

-$95M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$372M

Total Liabilities

$105M

Stockholders' Equity

$267M

Cash & Equivalents

$223M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$2M	-41.1%
Gross Profit	-$81M	$2M	-4507.0%
Operating Income	-$108M	-$114M	+5.0%
Net Income	-$110M	-$116M	+5.2%

LXRX FY 2012 Earnings — Lexicon Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena